Knowledge HQ

Discover a game-changing approach to T cell expansion. This application note showcases how the G-Rex bioreactor and Bio-Techne reagents deliver hands-free, zero-touchpoint cell growth. Learn how to streamline your manufacturing, boost efficiency, and maintain cell health—all with a simple fill-and-forget workflow.

Ignacio Nunez, COO of CellReady, discusses the importance of sustainability in cell and gene therapy manufacturing at ISCT 2024.

Ignacio Nunez, COO of CellReady, discusses current projects and what the future holds during ASGCT 2024.

Leading industry experts discuss critical strategies to make life-changing treatments more accessible and affordable for patients during ISCT 2024. Hear from top executives at Germfree, Cellular Origins, and CellReady as they discuss innovative solutions to overcome industry challenges. Moderated by ScaleReady.

For Cell and Gene Modified Cell Therapy (CGT) manufacturing, a robust contamination control strategy (CCS) is necessary to ensure compliance with current Good Manufacturing Practices (cGMP). A successful CCS helps ensure safety, purity, efficacy, and quality of a CGT product. CGT manufacturers should implement Closed Systems wherever possible and employ equipment that maintains a stable, clean environment with advanced monitoring. We show that Closed System G-Rex® bioreactors combined with Thermo ScientificTM HeracellTM ViosTM CR carbon dioxide (CO2) incubators enable simplified parallel processing capabilities and significantly reduced contamination risks in a highly efficient production.

Rizwan Chaudrey spoke with Ignacio Núñez, COO, CellReady, at ISCT 2024  about the company, its relationship with ScaleReady, what they are showcasing tat ISCT and what makes them unique.

In this application, the health of Triple Knock-Out (KO) transfected T-cells was evaluated by measuring cell expansion and viability in a Gas Permeable Rapid Expansion (G-Rex® - Wilson Wolf Manufacturing, LLC) platform using different cell culture media and cytokine supplement.

The G-Rex® Grant Program is empowering CGT manufacturers with resources and expertise and is a $20 million initiative by ScaleReady, Wilson Wolf Manufacturing, Bio-Techne, and CellReady, that is designed to propel the advancement of cell and gene therapies (CGT).  If you’re engaged in pre-clinical research, process development, or cGMP manufacturing of cell and gene-modified cell therapies, this program is for you!

Review the official description and outline of the new G-Rex® Grant Program, which empowers CGT manufacturers with resources and expertise. This $20 million initiative by ScaleReady, Wilson Wolf Manufacturing, Bio-Techne, and CellReady is designed to propel the advancement of cell and gene therapies (CGT).

Multiply Labs, a robotics company developing industry-leading automated manufacturing systems to produce individualized drugs, and Wilson Wolf, an innovative leader in cell and gene-modified cell (CGT) manufacturing technology, today announced a collaboration around the automation of Wilson Wolf’s G-Rex® bioreactors.

To better optimize their manufacturing process for a current clinical trial and IND amendment, AgonOx and Providence began to look for products to close and streamline key portions of the established manufacturing process for a shared project. It was imperative to find products that would maintain established levels of cell recovery, viability, and efficacy.